These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 27943173)

  • 1. Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine.
    Paulden M; O'Mahony JF; McCabe C
    Pharmacoeconomics; 2017 Jan; 35(1):5-13. PubMed ID: 27943173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.
    Siegel JE; Torrance GW; Russell LB; Luce BR; Weinstein MC; Gold MR
    Pharmacoeconomics; 1997 Feb; 11(2):159-68. PubMed ID: 10172935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NICE's selective application of differential discounting: ambiguous, inconsistent, and unjustified.
    O'Mahony JF; Paulden M
    Value Health; 2014 Jul; 17(5):493-6. PubMed ID: 25128041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discounting and decision making in the economic evaluation of health-care technologies.
    Claxton K; Paulden M; Gravelle H; Brouwer W; Culyer AJ
    Health Econ; 2011 Jan; 20(1):2-15. PubMed ID: 21154521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.
    Sanders GD; Neumann PJ; Basu A; Brock DW; Feeny D; Krahn M; Kuntz KM; Meltzer DO; Owens DK; Prosser LA; Salomon JA; Sculpher MJ; Trikalinos TA; Russell LB; Siegel JE; Ganiats TG
    JAMA; 2016 Sep; 316(10):1093-103. PubMed ID: 27623463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A normative perspective on discounting health outcomes.
    Oliver A
    J Health Serv Res Policy; 2013 Jul; 18(3):186-9. PubMed ID: 23760622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis.
    Schad M; John J
    Eur J Health Econ; 2012 Apr; 13(2):127-44. PubMed ID: 21170731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panel on cost-effectiveness in health and medicine recommendations: identifying costs.
    Manning WG
    J Clin Psychiatry; 1999; 60 Suppl 3():54-6; discussion 57-8. PubMed ID: 10073379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of the 1997 Canadian guidelines on the conduct of Canadian-based economic evaluations in the published literature.
    Lim ME; Bowen JM; O'Reilly D; McCarron CE; Blackhouse G; Hopkins R; Goeree R; Tarride JE
    Value Health; 2010; 13(2):328-34. PubMed ID: 19804434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health economic assessment: a methodological primer.
    Simoens S
    Int J Environ Res Public Health; 2009 Dec; 6(12):2950-66. PubMed ID: 20049237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the usefulness of budget impact analyses: a U.S. payer perspective.
    Watkins JB; Danielson D
    Value Health; 2014; 17(1):3-4. PubMed ID: 24438711
    [No Abstract]   [Full Text] [Related]  

  • 14. Recommendations of the Panel on Cost-effectiveness in Health and Medicine.
    Weinstein MC; Siegel JE; Gold MR; Kamlet MS; Russell LB
    JAMA; 1996 Oct; 276(15):1253-8. PubMed ID: 8849754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Future Costs, Fixed Healthcare Budgets, and the Decision Rules of Cost-Effectiveness Analysis.
    van Baal P; Meltzer D; Brouwer W
    Health Econ; 2016 Feb; 25(2):237-48. PubMed ID: 25533778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis in the nursing literature, 1992-1996.
    Allred CA; Arford PH; Mauldin PD; Goodwin LK
    Image J Nurs Sch; 1998; 30(3):235-42. PubMed ID: 9753838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of discounting in national health economic evaluation guidelines: healthcare value implications.
    Williams AO; Rojanasarot S; McGovern AM; Kumar A
    J Comp Eff Res; 2023 Feb; 12(2):e220167. PubMed ID: 36476014
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine.
    Russell LB; Gold MR; Siegel JE; Daniels N; Weinstein MC
    JAMA; 1996 Oct; 276(14):1172-7. PubMed ID: 8827972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].
    Lakdawalla DN; Doshi JA; Garrison LP; Phelps CE; Basu A; Danzon PM
    Value Health; 2018 Feb; 21(2):131-139. PubMed ID: 29477390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Guidelines for budget impact analysis of health technologies in Brazil].
    Ferreira-Da-Silva AL; Ribeiro RA; Santos VC; Elias FT; d'Oliveira AL; Polanczyk CA
    Cad Saude Publica; 2012 Jul; 28(7):1223-38. PubMed ID: 22729254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.